



Docket No. A013US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: BROWNING, et al.

Serial No.: 09/299,139

Filing Date: April 23, 1999

For: Soluble Lymphotoxin-Beta Receptors and Anti-Lymphotoxin Receptor and Ligand Antibodies, as Therapeutic Agents for the Treatment of Immunological Disease

RECEIVED  
AUG 22 2000  
TECH CENTER 1600/2000

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office as first class mail under C.F.R. 1.8 and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date:

August 7, 2000

Signature:

Judith A. Herrik

SEQUENCE LISTING

Applicant hereby submits a diskette containing a machine-readable copy of the Sequence Listing done in FastSeq Version 4.0 format.

The contents of the Sequence Listing diskette submitted herewith are the same as the contents of the paper form of the Sequence Listing submitted herewith. The sequences on the diskette and on the paper listing are identical to the sequences submitted in the application as filed.

Please charge our deposit account 02-2327 for any deficiencies.

Date:

8/7/00

Respectfully submitted,

Niki D. Cox

Niki D. Cox  
Reg. No. 42,446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
617/ 679-2079 (Direct)

# SEQUENCE LISTING

<130> Biogen, Inc.  
Browning, et al.

<130> Soluble Lymphotoxin Beta Receptor and  
Anti-Lymphotoxin Receptor and Ligand Antibodies as  
Therapeutic Agents for the Treatment of Immunological  
Diseases

<130> A013US

<140> 09/299,139

<141> 1999-04-23

<150> PCT/US97/19436

<151> 1997-10-24

<150> 60/029,060

<151> 1996-10-25

<160> 1

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 197

<212> PRT

<213> Homo Sapien

<400> 1

Ser	Gln	Pro	Gln	Ala	Val	Pro	Pro	Tyr	Ala	Ser	Glu	Asn	Gln	Thr	Cys
1				5					10					15	
Arg	Asp	Gln	Glu	Lys	Glu	Tyr	Tyr	Glu	Pro	Gln	His	Arg	Ile	Cys	Cys
		20						25					30		
Ser	Arg	Cys	Pro	Pro	Gly	Thr	Tyr	Val	Ser	Ala	Lys	Cys	Ser	Arg	Ile
	35					40						45			
Arg	Asp	Thr	Val	Cys	Ala	Thr	Cys	Ala	Glu	Asn	Ser	Tyr	Asn	Glu	His
	50					55				60					
Trp	Asn	Tyr	Leu	Thr	Ile	Cys	Gln	Leu	Cys	Arg	Pro	Cys	Asp	Pro	Val
65					70				75					80	
Met	Gly	Leu	Glu	Glu	Ile	Ala	Pro	Cys	Thr	Ser	Lys	Arg	Lys	Thr	Gln
			85						90					95	
Cys	Arg	Cys	Gln	Pro	Gly	Met	Phe	Cys	Ala	Ala	Trp	Ala	Leu	Glu	Cys
		100						105					110		
Thr	His	Cys	Glu	Leu	Leu	Ser	Asp	Cys	Pro	Pro	Gly	Thr	Glu	Ala	Glu
		115					120					125			
Leu	Lys	Asp	Glu	Val	Gly	Lys	Gly	Asn	Asn	His	Cys	Val	Pro	Cys	Lys
	130					135					140				
Ala	Gly	His	Phe	Gln	Asn	Thr	Ser	Ser	Pro	Ser	Ala	Arg	Cys	Gln	Pro
145					150					155				160	
His	Thr	Arg	Cys	Glu	Asn	Gln	Gly	Leu	Val	Glu	Ala	Ala	Pro	Gly	Thr
			165					170						175	
Ala	Gln	Ser	Asp	Thr	Thr	Cys	Lys	Asn	Pro	Leu	Glu	Pro	Leu	Pro	Pro

180  
Glu Met Ser Gly Thr  
195

185

190